The present invention provides compounds according to formula I and pharmaceutically acceptable salts and esters thereof, having the designations provided herein and which inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity.
1
Substituted Dihydroimidazoles and their Use in the Treatment of Tumors
申请人:Chamoin Sylvie
公开号:US20100075966A1
公开(公告)日:2010-03-25
The invention relates to dihydroimidazoles of formula rac-(I),
wherein the radicals and symbols are as defined herein; their use as inhibitors of the interaction of the MDM2 protein with a p53-like peptide, new pharmaceutical formulations comprising said compounds, said compounds for use in the therapeutic treatment of warm-blooded animals, especially humans, their use in the treatment of proliferative diseases or for the manufacture of pharmaceutical formulations useful in the treatment of proliferative diseases that respond to modulation of the interaction of the MDM2 protein with a p53-like peptide, a pharmaceutical formulation e.g. useful in the treatment of proliferative diseases that respond to modulation of the interaction of the MDM2 protein with a p53-like peptide comprising said compound, methods of treatment comprising administration of said compounds to a warm-blooded animal, and/or processes for the manufacture of said compounds.
[EN] CIS-2,4,5- TRIPHENYL-IMIDAZOLINES AND THEIR USE IN THE TREATMENT OF TUMORS<br/>[FR] CIS-2,4,5- TRIPHENYL-IMIDAZOLINES ET LEURS UTILISATIONS DANS LE TRAITEMENT DES TUMEURS
申请人:HOFFMANN LA ROCHE
公开号:WO2003051359A1
公开(公告)日:2003-06-26
The present invention provides compounds according to formula I and formula II and pharmaceutically acceptable salts ad esters thereof, having the designations provides herein and which inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity. Formula (I).
[EN] CIS-IMIDAZOLINES AS MDM2 INHIBITORS<br/>[FR] CIS-IMIDAZOLINES INHIBITEURS DE MDM2
申请人:HOFFMANN LA ROCHE
公开号:WO2003051360A1
公开(公告)日:2003-06-26
The present invention provides compounds according to formula I and formula II and pharmaceutically acceptable salts and esters thereof, having the designations provided herein and which inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity (I) (II).
The present invention provides compounds according to formula I and formula II and pharmaceutically acceptable salts and esters thereof, having the designations provided herein and which inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity.
1